MedDataX Logo

PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients

NCT ID: NCT01020604

Last Updated: 2013-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1376 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2013-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure after radical prostatectomy. Other prospective studies have shown no adverse effect of obesity on long-term outcomes after prostatectomy. Limited reports are available on the impact of obesity on prostate cancer progression after radiotherapy. Primary: to assess percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Secondary: to determine the Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer Obesity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

BMI Prostate cancer Recurrence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically proven prostate cancer patients being on adjuvant Zoladex treatment after primary therapy or on adjuvant therapy without primary curative therapy

Exclusion Criteria

-Prostate cancer patients refractory to hormonal therapy, not agreeing to participate, allergy against treatment
Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Istvan Buzogany

Role: PRINCIPAL_INVESTIGATOR

Budapest City's Local Government "Péterfy Sándor" Hospital and Ambulatory Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Baja, , Hungary

Site Status

Research Site

Barcs, , Hungary

Site Status

Research Site

Békés, , Hungary

Site Status

Research Site

Békéscsaba, , Hungary

Site Status

Research Site

Budapest, , Hungary

Site Status

Research Site

Csongrád, , Hungary

Site Status

Research Site

Debrecen, , Hungary

Site Status

Research Site

Dunaharaszti, , Hungary

Site Status

Research Site

Dunaújváros, , Hungary

Site Status

Research Site

Győr, , Hungary

Site Status

Research Site

Gyula, , Hungary

Site Status

Research Site

Helvécia, , Hungary

Site Status

Research Site

Jászberény, , Hungary

Site Status

Research Site

Kaposvár, , Hungary

Site Status

Research Site

Kecskemét, , Hungary

Site Status

Research Site

Kiskunhalas, , Hungary

Site Status

Research Site

Kőszárhegy, , Hungary

Site Status

Research Site

Makó, , Hungary

Site Status

Research Site

Miskolc, , Hungary

Site Status

Research Site

Nagyvenyim, , Hungary

Site Status

Research Site

Nyíregyháza, , Hungary

Site Status

Research Site

Nyírpazony, , Hungary

Site Status

Research Site

Orosháza, , Hungary

Site Status

Research Site

Pápa, , Hungary

Site Status

Research Site

Pécs, , Hungary

Site Status

Research Site

Salgótarján, , Hungary

Site Status

Research Site

Szeged, , Hungary

Site Status

Research Site

Szekszárd, , Hungary

Site Status

Research Site

Szentendre, , Hungary

Site Status

Research Site

Székesfehérvár, , Hungary

Site Status

Research Site

Szolnok, , Hungary

Site Status

Research Site

Szombathely, , Hungary

Site Status

Research Site

Tiszaföldvár, , Hungary

Site Status

Research Site

Veszprém, , Hungary

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hungary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-OHU-ZOL-2009/1

Identifier Type: -

Identifier Source: org_study_id